Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Stephanie Yohay, Soyoung Kim, Mingqian Lin, Temitope Oloyede, Ravi Narra, Sabarinath Radhakrishnan, Meera Mohan, Binod Dhakal, Marcelo Pasquini, Anita D'Souza, Othman Akhtar

Blood (2025) 146 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2025-6360

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Prashant Kapoor, Shikun Wang, Divaya Bhutani, Susan Bal, Keith Stockerl-Goldstein, Sherin Selvan, Othman Akhtar, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 694.

https://doi.org/10.1182/blood-2025-694

Published: 2025

Journal Articles

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Abhishek Janardan, Pranav Jumin, Abigail Thorgerson, Ravi Kishore Narra, Othman Akhtar, Sabarinath Radhakrishnan, Marcelo Pasquini, Binod Dhakal, Anita D'Souza, Meera Mohan

Blood (2025) 146 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2025-2800

Published: 2025

Journal Articles

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Binod Dhakal, Maria Hintzke, Othman Akhtar, Jamila Mammadova, Adetola Kassim, Marcelo Pasquini, Meera Mohan, Ravi Kishore Narra, Sabarinath Radhakrishnan, Fumou Sun, Anita D'Souza, Maher Albitar, Bhagirathbhai Dholaria

Blood (2025) 146 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2025-2240

Published: 2025

Journal Articles

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

Khanmi Kasomva, Kirthi Pulakanti, Josiah Murray, Kritika Yadav, Ravi Narra, Marcelo Pasquini, Anita D'Souza, Meera Mohan, Othman Akhtar, Deepak Parashar, Fumou Sun, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood (2025) 146 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2025-5716

Published: 2025

Journal Articles

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Muhammad Bilal Abid, Kitsada Wudhikarn, Qiran Ye, Michael Martens, Abu-Sayeef Mirza, Lohith Gowda, Srinivas Devarakonda, Yvonne Efebera, Zeinab El Boghdadly, Christopher Dandoy, Othman Akhtar, Temitope Oloyede, Christen Ebens, Joshua Hill, Hemant Murthy, Miguel-Angel Perales, Anna Huppler, Jeffery Auletta

Blood (2025) 146 (Supplement 1): 716.

https://doi.org/10.1182/blood-2025-716

Published: 2025

Journal Articles

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Meera Mohan, Aniko Szabo, Ravi Kishore Narra, Catharine Skoog, Areyl Goff, Binod Dhakal, Othman Akhtar, Marcelo Pasquini, Sabarinath Radhakrishnan, Sridhar Rao, Subramaniam Malarkannan, Carolina Schinke, Leo Rasche, Anita D'Souza

Blood (2025) 146 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2025-5758

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only